<DOC>
	<DOCNO>NCT01641406</DOCNO>
	<brief_summary>The purpose study evaluate novel neoadjuvant regimen invasive breast carcinoma use MD Anderson residual cancer burden score.To prospectively evaluate utility PET scan guide neoadjuvant treatment utility Oncotype test stratifier treatment decisons ER+/Her2- patient . To evaluate clinical anti-tumor activity neoadjuvant hormonal therapy ER+/Her2 negative patient . To evaluate prognostic factor associate associated pathological response measure residual cancer burden tool .</brief_summary>
	<brief_title>`` Phase II Study PET Guided Neoadjuvant Chemotherapy ( NAC ) Oncotype Guided Hormonal Therapy Breast Cancer ''</brief_title>
	<detailed_description>Treatment propose TEC-NAX triple negative Her2+ case . For Er+/Her2- case , propose use PET scan guide therapy first course TEC . Those drop SUV≤5 % , treatment modify use Oncotype test . Those Her2 negative patient whose response first 4 course induction TEC le complete remission , tretment change second line regimen , Navelbine-Avastin-Xeloda ( NAX ) , intention capture good response prior surgery . Those Her2+ initially also receive TEC subsequent therapy include Trastuzumab ( Herceptin ) whether thet respond wellor TEC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Previously untreated ( chemotherapy , hormonal radiation therapy ) invasive breast cancer . Diagnosis invasive ductal lobular breast cancer plus minus DCIS . Inflammatory carcinoma also elegible . Age≥ 18 year Only female patient eligible Tumor≥ 1.0cm MRI and/or sonographic clinical exam measurement . If tumor &lt; 1.0 patient biopsy proven lymph node metastasis , also consider eligible.Although tumors≥2cm consideredmeasurable RECIST criterion , nevertheless include tumors≥1cm since primary endpoint pathological CR rate . Performance status ECOG≤2 Karnofsky≥ 50 % Peripheral neuropathy≤ grade 1 Hematologic ( minimal value ) : Absolute Neutrophil count≥1,500/mm³ ; Hemoglobin≥8.0g/dl ; Paltelet count≥100,000/mm³ Hepatic ; Total bilirubin≤ULN AST ALT ALP within range . In determine eligibility abnormal two value ( AST ALT ) use per protocol table p.24of 69 . Women childbearing potential must negative pregnancy test Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Renal ; urine protein : creatinine ( UPC ) ratio1.0 screen urine dipstick proteinuria &lt; 2+ ( patient discover have˃/=2+ protinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; /=1g protein 24 hr elegible Pregnant breast feeding patient exclude Patients second malignancy expect survival &lt; 5 year Previous chemotherapy Taxanes , Anthracyclines Cyclophosphamide . Patientes history severe hypersensitivity reaction Taxotere ( Docetaxel ) drug formulate polysorbate 80 . Pure DCIS diagnose elegible Special histology favorable prognosis mucinous , tubular elegible Patients reduce ejection fraction &lt; 50 % eligible Patients tumor &lt; 1.0cm unless biopsy proven axillary node metastasis present . Cardiac thrombotic event past 12 month Stroke transient ischemic attack ( TIA ) within 12 month poorly control hypertension define persistent blood pressure elevation˃150 systolic and/or 100 diastolic responsive medication . GI condition increase risk perforation within 6 month study Any serious nonhealing wound , ulcer , bone fracture . No minor surgical procedure within 7 day study entry major surgery within 28 day study entry anticipation need major surgical procedure course study . Significant vascular disease symptomatic peripheral vascular disease . Any evidence bleeding diathesis coagulopathy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>NAC Protocol</keyword>
	<keyword>NAC Oncotype Guided Hormonal therapy breast cancer</keyword>
	<keyword>Neoadjuvant Oncotype</keyword>
	<keyword>NAC CCAM 1101</keyword>
</DOC>